John Stagg

17PUBLICATIONS
150CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Human impacts of climate change and human adaptation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Apr 03, 2026
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Samya Aouad, Maleck Kadiri, David Allard

|Feb 19, 2026
The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.

Mariana Acevedo, Florence Dô, Firas El-Mortada

|Dec 09, 2024
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.

David Allard, Jeanne Cormery, Salma Bricha

|Nov 03, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

|Jul 07, 2023
The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.

John Stagg, Encouse Golden, Erik Wennerberg

|Jun 26, 2023
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

Fabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff

Pageof 3

Frequent Collaborators

4 joint publications

Laurence Buisseret

3 joint publications

Simon Turcotte

2 joint publications

Kevin Punie

2 joint publications

David Allard